Welcome to our dedicated page for Pulmonx news (Ticker: LUNG), a resource for investors and traders seeking the latest updates and insights on Pulmonx stock.
Pulmonx Corp (Nasdaq: LUNG) delivers innovative minimally invasive solutions for severe lung diseases, including its FDA-cleared Zephyr Valve system. This news hub provides essential updates for stakeholders tracking medical advancements and corporate developments in interventional pulmonology.
Access real-time updates on clinical trial milestones, regulatory approvals, and strategic partnerships that shape treatment paradigms for emphysema and COPD. Our curated collection features earnings reports, product launch details, and peer-reviewed research findings - all vital for understanding Pulmonx's market position.
Key content includes analysis of pulmonary treatment innovations, global commercialization efforts, and financial performance metrics. Investors and healthcare professionals will find timely information on FDA submissions, international expansion, and clinical outcome studies that demonstrate improved patient quality of life.
Bookmark this page for centralized access to Pulmonx's latest advancements in bronchoscopic lung volume reduction technology. Stay informed about developments that impact both respiratory care standards and long-term corporate growth strategies.
Pulmonx reported strong Q2 2022 results with worldwide revenue reaching $14.0 million, a 14% increase year-over-year. U.S. revenue surged 31% to $8.6 million, driven by Zephyr Valve procedures. Gross margin improved to 75%, up from 74% in Q2 2021. However, operating expenses rose 14% to $24.8 million, contributing to a net loss of $14.6 million or $0.40 per share. Pulmonx maintains its full-year revenue guidance of $55-$60 million.
Pulmonx Corporation (Nasdaq: LUNG), a leader in minimally invasive treatments for severe lung disease, will present at the Canaccord Genuity 42nd Annual Growth Conference in Boston on August 10, 2022, at 1:00 PM PT / 4:00 PM ET. A live and archived webcast of the event will be accessible on the company's Investors page. Pulmonx is known for its Zephyr® Endobronchial Valve, which has treated over 25,000 patients worldwide, and received FDA premarket approval as a breakthrough device.
Pulmonx Corporation (NASDAQ: LUNG) will announce its Q2 2022 financial results on August 2, 2022, after market close. A conference call will be held at 1:30 p.m. PT (4:30 p.m. ET) to discuss these results. Pulmonx is a leader in minimally invasive treatments for lung disease, notably through its FDA-approved Zephyr® Endobronchial Valve, which is available in over 25 countries. The company has treated more than 25,000 patients with over 100,000 valves used.
Pulmonx Corporation (LUNG) reported Q1 2022 financial results, highlighting a 17% increase in worldwide revenue to $10.8 million compared to Q1 2021. U.S. revenue surged 40% to $6.0 million, driven by growth in Zephyr Valve procedures. Gross margin improved to 75%, up from 72%, despite operating expenses rising 24% to $23.8 million. The net loss for the quarter was $15.8 million, or $0.43 per share. Pulmonx maintains its 2022 revenue outlook of $55 million to $60 million amidst ongoing investments and challenges from COVID and foreign exchange rates.
Pulmonx Corporation (Nasdaq: LUNG), a leader in minimally invasive treatments for severe lung disease, will present at the Bank of America Securities 2022 Healthcare Conference on May 10, 2022, at 12:40 PM PT. A live and archived webcast will be available on the company's investor website. Pulmonx is known for its innovative Zephyr Valve, which treats patients with severe emphysema/COPD and has received FDA breakthrough device designation. The valve is commercialized in over 25 countries, with more than 100,000 units used to date.
Pulmonx Corporation (Nasdaq: LUNG) will release its Q1 2022 financial results on May 3, 2022, after market close. Management will host a conference call at 1:30 p.m. PT / 4:30 p.m. ET to discuss the results. Investors can participate by calling (833) 614-1518 domestically or (270) 823-1072 internationally, using Conference ID: 2575271. The event will also be accessible via a live and archived webcast on the company's website.
Pulmonx Corporation (LUNG) reported strong financial results for Q4 and full year 2021, with Q4 revenue reaching $13.7 million (+39%) and full-year revenue at $48.4 million (+48%). The company achieved a gross margin of 74.8% in Q4, up from 72.0% in 2020. Operating expenses increased by 38% to $22.6 million in Q4, leading to a net loss of $13.0 million. For 2022, Pulmonx forecasts revenues between $55 million and $60 million, despite ongoing COVID-19 impacts.
Pulmonx Corporation (Nasdaq: LUNG) announced its participation in the Citi 2022 Virtual Healthcare Conference on February 24, 2022, at 8:45 AM PT / 11:45 AM ET. The event will feature a fireside chat with the company's leaders discussing their innovative treatments for severe lung disease. A live and archived webcast will be available on the Investors section of Pulmonx's website. Pulmonx specializes in minimally invasive solutions, notably the Zephyr® Endobronchial Valve, which has been approved by the FDA and is available in over 25 countries, treating more than 25,000 patients.
Pulmonx Corporation (Nasdaq: LUNG) will release its financial results for Q4 and full year 2021 on February 23, 2022, after market close. A conference call will follow at 1:30 p.m. PT / 4:30 p.m. ET for discussion and analysis of the results. Investors can participate via phone or through a live webcast available on Pulmonx's investor website. Pulmonx is recognized for its minimally invasive solutions for severe lung disease, including the Zephyr® Endobronchial Valve, which has treated over 25,000 patients globally.
Pulmonx Corporation (Nasdaq: LUNG) has announced its participation in the 40th Annual J.P. Morgan Healthcare Conference on January 11, 2022, at 7:30 a.m. EST. The presentation will be accessible via a live and archived webcast on the company’s investors webpage.
Pulmonx is recognized for its innovative solutions for severe lung disease, notably the Zephyr® Endobronchial Valve, which has received FDA pre-market approval. The valve is currently available in over 25 countries, having been used in more than 25,000 patients worldwide.
FAQ
What is the current stock price of Pulmonx (LUNG)?
What is the market cap of Pulmonx (LUNG)?
